有心肌梗死病史的住院患者发生急性肾损伤后心血管药物的使用情况
这项基于人群的队列研究纳入66岁及以上有心肌梗死病史且住院期间发生急性肾损伤并存活的患者,按倾向性评分与无急性肾损伤患者1:1匹配。结果显示急性肾损伤与出院1年内3类心血管药物(ACEi/ARB、他汀、β受体阻滞剂)配药频率较低相关,在2期和3期急性肾损伤患者中最为明显。
要点
- 急性肾损伤存活者出院1年内3类心血管药物配药较少(sHR 0.93)。
- 2期(sHR 0.81)和3期(sHR 0.71)急性肾损伤者配药减少最明显。
- 3期急性肾损伤者他汀(sHR 0.85)和β受体阻滞剂(sHR 0.86)配药较少。
核心结论
- 有心肌梗死病史的患者中,急性肾损伤存活者出院1年内接受ACEi/ARB、他汀或β受体阻滞剂处方的可能性较低,该关联在2期和3期急性肾损伤患者中最为明显。
研究设计与样本
- 基于人群的队列研究,纳入66岁及以上有心肌梗死病史且住院期间发生急性肾损伤并存活的患者,按倾向性评分与无急性肾损伤患者1:1匹配。
主要发现
- 共识别28,871例急性肾损伤患者,其中21,452例与无急性肾损伤患者1:1匹配。
- 匹配队列平均年龄80岁,40%为女性,34%在索引住院期间发生心肌梗死。
- 急性肾损伤与出院1年内全部3类心血管药物配药频率较低相关(sHR 0.93;95%CI 0.91-0.95)。
- 该关联在2期(sHR 0.81;95%CI 0.75-0.88)和3期(sHR 0.71;95%CI 0.64-0.79)急性肾损伤患者中最为明显。
- 2期(sHR 0.87;95%CI 0.81-0.92)和3期(sHR 0.85;95%CI 0.78-0.93)急性肾损伤患者他汀配药较少,3期急性肾损伤患者β受体阻滞剂配药较少(sHR 0.86;95%CI 0.79-0.94)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients who survive acute kidney injury (AKI) may receive fewer cardioprotective drugs. Our objective was to measure the difference in time to dispensing of evidence-based cardiovascular drugs in patients with a history of myocardial infarction (MI) with and without AKI. METHODS: This was a population-based cohort study of patients 66 years of age and older with a history of MI who survived a hospitalization complicated with AKI, propensity-score matched to patients without AKI. The primary outcome was time to outpatient dispensing of an angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), statin, or β-blocker within 1 year of hospital discharge. RESULTS: We identified 28,871 patients with AKI, of whom 21,452 were matched 1:1 to patients without AKI. In the matched cohort, mean age was 80 years, 40% were female, and 34% had an MI during the index hospitalization. AKI was associated with less frequent dispensing of all 3 cardiovascular drug classes within 1 year of hospital discharge (subdistribution hazard ratio [sHR], 0.93; 95% confidence interval [CI], 0.91-0.95). This association was most pronounced in patients with stage 2 (sHR, 0.81; 95% CI, 0.75-0.88) and stage 3 (sHR, 0.71; 95% CI, 0.64-0.79) AKI. We observed less frequent dispensing of statins in patients with stage 2 (sHR, 0.87; 95% CI, 0.81-0.92) and stage 3 (sHR, 0.85; 95% CI, 0.78-0.93) AKI and less frequent dispensing of β-blockers in patients with stage 3 AKI (sHR, 0.86; 95% CI, 0.79-0.94). CONCLUSION: In patients with a history of MI, survivors of AKI were less likely to receive prescriptions for ACEi/ARB, statins, or β-blockers within 1 year of hospital discharge. This association was most pronounced in patients with stages 2 and 3 AKI.
引用
- Meraz-Muñoz AY, Jeyakumar N, Luo B, et al. Cardiovascular Drug Use After Acute Kidney Injury Among Hospitalized Patients With a History of Myocardial Infarction. Kidney Int Rep. 2022. PMID: 36815105. doi:10.1016/j.ekir.2022.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。